Open AccessDurable response after the discontinuation of pembrolizumab treatment due to an adverse event in a patient with advanced endometrial cancer: A case report
Author(s) -
Shuntaro Umihira,
Takahiro Koyanagi,
Kohei Tamura,
Yoshifumi Takahashi,
Takahiro Yoshiba,
Suzuyo Takahashi,
Akiyo Taneichi,
Yasushi Saga,
Yuji Takei,
Hiroyuki Fujiwara
Publication year - 2022
Publication title -
experimental and therapeutic medicine
Language(s) - English
Resource type - Journals
eISSN - 1792-1015
pISSN - 1792-0981
DOI - 10.3892/etm.2022.11336
Subject(s) - pembrolizumab , medicine , discontinuation , adverse effect , cancer , endometrial cancer , oncology , nivolumab , surgery , immunotherapy
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom